Dr Jotte speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about treating stage IV squamous NSCLC with anti-PD-L1 atezolizumab and chemotherapy.

In this study, 29% of all patients, regardless of PD-L1 expression, had a reduced risk of disease worsening or death, compared with those who received chemotherapy alone.

He also describes a doubling of progression-free survival (PFS) benefit with this combination, noting that this came with an increased rate of severe side effects.

For more on these results, watch his presentation of the results at the conference, and read our news coverage here.
[ Ссылка ]
[ Ссылка ]

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть